Geron Corporation (GERN) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Geron Corporation.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.399 Hello and welcome to the GERON first quarter 2025 earnings call. 00:00:05.399 -- 00:00:09.124 All lines have been placed on mute to prevent any background noise. 00:00:09.124 -- 00:00:13.010 After the speaker's remarks, there will be a question and answer session. 00:00:13.010 -- 00:00:17.176 If you would like to ask a question during this time, please press star 1 on your telephone 00:00:17.176 -- 00:00:18.718 keypad. 00:00:18.718 -- 00:00:24.066 I would now like to turn the conference over to Ron Moldaver, Investor Relations. 00:00:24.066 -- 00:00:25.883 You may begin. 00:00:25.883 -- 00:00:30.088 Good morning, everyone. Welcome to the Jaron Corporation first quarter 2025 earnings 00:00:30.088 -- 00:00:34.373 conference call. Before we begin, please note that during the course of this presentation 00:00:34.373 -- 00:00:38.038 and question and answer session, we will be making forward-looking statements regarding 00:00:38.038 -- 00:00:43.084 future events, performance, plans, expectations, and other projections, including those 00:00:43.084 -- 00:00:47.830 related to the launch, commercial opportunity, and therapeutic potential of Ritello, 00:00:47.830 -- 00:00:52.624 anticipated clinical and commercial events, and related timelines, the sufficiency of 00:00:52.624 -- 00:00:57.151 Jerron's financial resources and other statements that are not historical facts. 00:00:57.151 -- 00:01:00.276 Actual events or results could differ materially. 00:01:00.276 -- 00:01:05.124 Therefore, I refer you to the discussion under the heading Risk Factors in Jerron's most 00:01:05.124 -- 00:01:10.293 recent periodic report with the SEC, which identifies important factors that could 00:01:10.293 -- 00:01:14.600 cause actual results to differ material...